Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period

Abstract

Background Interleukin-23 inhibitors are novel treatment options for psoriasis, and their efficacy and safety have been widely demonstrated in phase 3 clinical trials. Nonetheless, their real-world data remain limited, especially in Asia. Objective To evaluate the real-world effectiveness of interleukin-23 inhibitor guselkumab in Chinese patients with psoriasis. Methods In this retrospective single-center study, Chinese patients with psoriasis receiving a standard dose of guselkumab from November 2018 to May 2020 were included in the study cohort. Disease assessment was performed at baseline (Week 0), and at Week 4, 12, and 20 thereafter, using Psoriasis Area and Severity Index (PASI) score. Results Data of 68 adult patients with psoriasis were retrieved for analysis. At Week 20, 72.1%/47.1% of the patients achieved PASI 90/100 response respectively, and 76.5% achieved a PASI score <3. Baseline mean PASI score was 17.5, which significantly reduced to 2.0 at Week 20 (P=0.000). No previous use of biologics was a single significant factor associated with achieving PASI 90/100 and PASI score <3 responses at Week 20 (all Ps<0.05), while there were no statistically significant differences between males and females and body weight >75 and ≤75 kg in achieving these responses (all Ps>0.05). Adverse events were experienced by five patients (7.4%), and all were mild in severity. Conclusion In this first real-world study on guselkumab among Chinese patients with psoriasis, this biologics was shown to be safe and effective in reaching an optimal clinical response up to 20 weeks.

Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

“…Similarly, in a real-world analysis of 44 patients 270 with psoriasis receiving guselkumab, PASI 75, PASI 90 and PASI 100 were 95.5%, 59.1% and 16%, respectively, at 6 months [22]. Comparable results were also seen in a cohort of 68 patients in China followed for 20 weeks: PASI 90, 72.1% and PASI 100, 47.1% [23]. Megna et al carried out a real-life analysis of 23 patients with moderate-to-severe psoriasis treated with guselkumab who were followed for 44 weeks, reporting that the mean PASI score decreased to 0.8 at study end from a baseline value of 15.1 [24].…”

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry

“…In addition to having evaluated patients with a broad range of psoriasis IGA severities, this study is unique compared with most other real-world analyses of guselkumab in that it included prospectively collected data, assessed a larger number of patients, had a longer treatment duration, and/or evaluated a more comprehensive panel of disease activity scores and PROMs [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]. Previous studies have typically been retrospective analyses of patients who received guselkumab for B 28 weeks and primarily focused on PASI outcomes-none appear to have reported on IGA, WPAI, or EQ-VAS scores or changes in several disease-specific symptoms.…”

“…Real-world data can provide valuable insights on the experience of patients who would typically be excluded from randomized controlled trials (RCTs) as they would not meet study eligibility criteria. Several recent studies have evaluated the real-world effectiveness and safety of guselkumab in psoriasis, showing favorable outcomes on the PASI and a limited number of other disease activity assessments and PROMs [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]. However, most of these investigations included patients with moderateto-severe disease, had relatively short durations of treatment, evaluated few endpoints, and/or included populations located outside of the USA and Canada.…”

The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis

“…Instead, current treatment guidelines refer to absolute values, e.g., PASI <3 and the Dermatology Life Quality Index (DLQI) ≤5 [2][3][4][5]. However, although several studies have evaluated the real-world effectiveness of individual IL-17 or IL-23 drugs in psoriasis by PASI and DLQI [6][7][8][9][10][11][12][13][14][15][16][17][18], few have yet assessed the absolute values. The objective of this study was to analyze treatment response and proportions of patients that reach the treatment targets in terms of clinical and HRQoL outcomes in patients using IL-17 and IL-23 inhibitors in clinical practice.…”